A trusted advisor – Transforming patients’ lives with pioneering molecular diagnostics.

A prognostic and predictive test to guide ER+, HER2-, N0 and N+ breast cancer treatment decisions

A Gene Expression Test
to stratify patients
according to Prostate Cancer
Aggressiveness

The latest advance in
hereditary Cancer testing

The most comprehensive
HRD tumor test to guide
PARP inhibitor treatment

previous arrow
next arrow
Slider

Management Message

Raymond Francot, Executive Vice President, International Operations

Myriad Genetics is the pioneer and worldwide leader in molecular diagnostics, offering innovative products that transform patients’ lives. Our products include tests for hereditary cancer, urological and breast cancer prognosis, carrier screening, melanoma diagnosis, depression, and autoimmune disorders. Myriad has partnered with several leading pharmaceutical companies to provide companion diagnostics to identify patients who can benefit from new cancer therapies.

Read more

Our Mission

Our Products

Myriad offers an array of genetic tests, prognostic tests, and personalized medicine tests to healthcare providers to help them assess a patient’s increased cancer risk, disease aggressiveness, optimize efficacy of chemotherapy and identify patients most suitable for therapy.

Our Pipeline

Myriad possesses the deepest diagnostic pipeline across the disease spectrum, including clinical tests in areas of unmet medical need such as autoimmune diseases, dermatology, neuroscience, oncology, urology and women’s health. Myriad’s research investment totals $358 million over the past five years.

The Science

At Myriad, we use state-of-the art technologies including DNA sequencing, RNA analysis and proteomics to innovate and create the next generation of breakthrough diagnostics.

Our talented scientists are working in collaboration with universities, biotech and pharmaceutical companies, and government agencies to accelerate the pace of innovation for patients worldwide. This approach affords us a diversity of perspectives as well as access to cutting-edge science regardless of where it resides.

Who We Are

31st European Congress of Pathology (ECP)

Myriad is looking forward to meeting you at

the 31st European Congress of Pathology (ECP)
Nice . September 7-11, 2019

Please visit us at booth # R21
and learn more about EndoPredict

44th European Society for Medical Oncology (ESMO)

Myriad is looking forward to meeting you at

44th European Society for Medical Oncology (ESMO)
Barcelona . September 27 – October 1, 2019

PPlease come and visit Myriad’s booth
and learn more about EndoPredict

News Center

  • All
  • Products

Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China SALT LAKE CITY, Nov. 16, 2020 (GLOBE…

German Federal Joint Committee (G-BA) Issues Nationwide Reimbursement Decision for EndoPredict® Breast Cancer Prognostic Test October 16, 2020 at 9:05 AM…

SALT LAKE CITY, Aug. 21, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and…

Publications Demonstrate the Ability of the PRS Component of riskScore® to Accurately Stratify Breast Cancer Risk in Women Both With and…

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

EndoPredict Predicts Response to Neoadjuvant Chemotherapy and Endocrine Therapy SALT LAKE CITY, June 04, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc.…

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision…